Otsuka (OTCMKTS:OTSKY) Hits New 52-Week High – Here’s Why

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $36.34 and last traded at $36.29, with a volume of 1949 shares traded. The stock had previously closed at $35.37.

Analysts Set New Price Targets

OTSKY has been the topic of a number of research analyst reports. Morgan Stanley upgraded Otsuka to an “overweight” rating in a research report on Friday, January 23rd. Zacks Research downgraded Otsuka from a “hold” rating to a “strong sell” rating in a report on Monday, March 2nd. UBS Group upgraded shares of Otsuka to a “hold” rating in a research report on Tuesday, January 27th. Finally, The Goldman Sachs Group cut shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce”.

Otsuka Stock Up 3.3%

The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The business has a 50-day simple moving average of $32.57 and a two-hundred day simple moving average of $29.60. The company has a market capitalization of $39.25 billion and a price-to-earnings ratio of 15.89.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.